|
11. |
Effects of AGI-1067 and Probucol After Percutaneous Coronary Interventions |
|
Circulation: Journal of the American Heart Association,
Volume 107,
Issue 4,
2003,
Page 552-558
Jean-Claude Tardif,
Jean Grégoire,
Leonard Schwartz,
Lawrence Title,
Louise Laramée,
François Reeves,
Jacques Lespérance,
Martial Bourassa,
Philippe L’Allier,
Mitchell Glass,
Jean Lambert,
Marie-Claude Guertin,
Preview
|
PDF (53KB)
|
|
摘要:
Background—AGI-1067, a metabolically stable modification of probucol, is an equipotent antioxidant to probucol but is pharmacologically distinct. In a multicenter trial, we studied whether AGI-1067 reduces restenosis assessed by intravascular ultrasound (IVUS) after percutaneous coronary intervention (PCI) compared with placebo and probucol used as a positive control.Methods and Results—Two weeks before PCI, 305 patients were randomly assigned to 1 of 5 treatment groups: placebo, probucol 500 mg BID, or AGI-1067 70, 140, or 280 mg once daily. Patients were treated for 2 weeks before and 4 weeks after PCI. Baseline and 6-month follow-up IVUS were interpreted by a blinded core laboratory. Stents were used in 85% of patients. Luminal area at the PCI site at follow-up was 2.66±1.58 mm2for placebo, 3.69±2.69 mm2for probucol, 2.75±1.76 mm2for AGI-1067 70 mg, 3.17±2.26 mm2for AGI-1067 140 mg, and 3.36±2.12 mm2for AGI-1067 280 mg (P=0.02 for the dose-response relationship;P≤0.05 for AGI-1067 280 mg and probucol versus placebo). There was a mean narrowing of 5.3 mm3of reference segment lumen in the placebo group and an enlargement in the AGI-1067 140- and 280-mg groups at follow-up (P=0.05 for 140 mg). An increase in QTc interval >60 ms occurred in 4.8% of placebo patients, 17.4% of probucol patients, and 4.8%, 2.4%, and 2.5% of patients in the AGI-1067 groups (P=0.02).Conclusions—AGI-1067 and probucol reduce restenosis after PCI. In contrast to probucol, AGI-1067 did not cause prolongation of the QTc interval and improved lumen dimensions of reference segments, suggestive of a direct effect on atherosclerosis.
ISSN:0009-7322
出版商:OVID
年代:2003
数据来源: OVID
|
12. |
TAXUS III TrialIn-Stent Restenosis Treated With Stent-Based Delivery of Paclitaxel Incorporated in a Slow-Release Polymer Formulation |
|
Circulation: Journal of the American Heart Association,
Volume 107,
Issue 4,
2003,
Page 559-564
Kengo Tanabe,
Patrick Serruys,
Eberhard Grube,
Pieter Smits,
Guido Selbach,
Willem van der Giessen,
Manfred Staberock,
Pim de Feyter,
Ralf Müller,
Evelyn Regar,
Muzaffer Degertekin,
Jurgen Ligthart,
Clemens Disco,
Bianca Backx,
Mary Russell,
Preview
|
PDF (102KB)
|
|
摘要:
Background—The first clinical study of paclitaxel-eluting stent for de novo lesions showed promising results. We performed the TAXUS III trial to evaluate the feasibility and safety of paclitaxel-eluting stent for the treatment of in-stent restenosis (ISR).Methods and Results—The TAXUS III trial was a single-arm, 2-center study that enrolled 28 patients with ISR meeting the criteria of lesion length ≤30 mm, 50% to 99% diameter stenosis, and vessel diameter 3.0 to 3.5 mm. They were treated with one or more TAXUS NIRx paclitaxel-eluting stents. Twenty-five patients completed the angiographic follow-up at 6 months, and 17 of these underwent intravascular ultrasound (IVUS) examination. No subacute stent thrombosis occurred up to 12 months, but there was one late chronic total occlusion, and additional 3 patients showed angiographic restenosis. The mean late loss was 0.54 mm, with neointimal hyperplasia volume of 20.3 mm3. The major adverse cardiac event rate was 29% (8 patients; 1 non-Q-wave myocardial infarction, 1 coronary artery bypass grafting, and 6 target lesion revascularization [TLR]). Of the patients with TLR, 1 had restenosis in a bare stent implanted for edge dissection and 2 had restenosis in a gap between 2 paclitaxel-eluting stents. Two patients without angiographic restenosis underwent TLR as a result of the IVUS assessment at follow-up (1 incomplete apposition and 1 insufficient expansion of the stent).Conclusions—Paclitaxel-eluting stent implantation is considered safe and potentially efficacious in the treatment of ISR. IVUS guidance to ensure good stent deployment with complete coverage of target lesion may reduce reintervention.
ISSN:0009-7322
出版商:OVID
年代:2003
数据来源: OVID
|
13. |
Short-Term Heart Rate Variability Strongly Predicts Sudden Cardiac Death in Chronic Heart Failure Patients |
|
Circulation: Journal of the American Heart Association,
Volume 107,
Issue 4,
2003,
Page 565-570
Maria La Rovere,
Gian Pinna,
Roberto Maestri,
Andrea Mortara,
Soccorso Capomolla,
Oreste Febo,
Roberto Ferrari,
Mariella Franchini,
Marco Gnemmi,
Cristina Opasich,
Pier Riccardi,
Egidio Traversi,
Franco Cobelli,
Preview
|
PDF (75KB)
|
|
摘要:
Background—The predictive value of heart rate variability (HRV) in chronic heart failure (CHF) has never been tested in a comprehensive multivariate model using short-term laboratory recordings designed to avoid the confounding effects of respiration and behavioral factors.Methods and Results—A multivariate survival model for the identification of sudden (presumably arrhythmic) death was developed with data from 202 consecutive patients referred between 1991 and 1995 with moderate to severe CHF (age 52±9 years, left ventricular ejection fraction 24±7%, New York Heart Association class 2.3±0.7; the derivation sample). Time- and frequency-domain HRV parameters obtained from an 8′ recording of ECG at baseline and during controlled breathing (12 to 15 breaths/min) were challenged against clinical and functional parameters. This model was then validated in 242 consecutive patients referred between 1996 and 2001 (validation sample). In the derivation sample, sudden death was independently predicted by a model that included low-frequency power (LFP) of HRV during controlled breathing ≤13 ms2and left ventricular end-diastolic diameter ≥77 mm (relative risk [RR] 3.7, 95% CI 1.5 to 9.3, and RR 2.6, 95% CI 1.0 to 6.3, respectively). The derivation model was also a significant predictor in the validation sample (P=0.04). In the validation sample, LFP ≤11 ms2during controlled breathing and ≥83 ventricular premature contractions per hour on Holter monitoring were both independent predictors of sudden death (RR 3.0, 95% CI 1.2 to 7.6, and RR 3.7, 95% CI 1.5 to 9.0, respectively).Conclusions—Reduced short-term LFP during controlled breathing is a powerful predictor of sudden death in patients with CHF that is independent of many other variables. These results refine the identification of patients who may benefit from prophylactic implantation of a cardiac defibrillator.
ISSN:0009-7322
出版商:OVID
年代:2003
数据来源: OVID
|
14. |
Myocardial Production of C-Type Natriuretic Peptide in Chronic Heart Failure |
|
Circulation: Journal of the American Heart Association,
Volume 107,
Issue 4,
2003,
Page 571-573
Paul Kalra,
Jonathon Clague,
Aidan Bolger,
Stefan Anker,
Phillip Poole-Wilson,
Allan Struthers,
Andrew Coats,
Preview
|
PDF (52KB)
|
|
摘要:
Background—C-type natriuretic peptide (CNP) is a vasodilator produced by the vascular endothelium. It shares structural and physiological properties with the cardiac hormones atrial natriuretic peptide and brain natriuretic peptide (BNP), but little is known about its pathophysiological role in chronic heart failure (CHF). We assessed the hypothesis that CNP is produced by the heart in patients with CHF.Methods and Results—Myocardial CNP production was determined (difference in plasma levels between the aortic root and coronary sinus [CS]) in 9 patients undergoing right and left heart catheterization as part of their CHF assessment (all male, age 59±9 years; New York Heart Association class 2.2±0.1; left ventricular ejection fraction 29±5%; creatinine 105±8 &mgr;mol/L [all values mean±SEM]). BNP, established as originating from myocardium, was assessed from the same samples as a positive control. Analyses were performed by a blinded operator using a standard competitive radioimmunoassay kit (Peninsula Laboratories, Bachem Ltd UK). A step-up (29%) in plasma CNP concentration was found from the aorta to the CS (3.55±1.53 versus 4.59±1.54 pg/mL, respectively;P=0.035). The mean increase in CNP was 0.90±0.35 pg/mL (range 0.05 to 2.80 pg/mL). BNP levels increased by 57% from aorta to CS (86.0±20.5 versus 135.0±42.2 pg/mL;P=0.01). CS CNP levels correlated with mean pulmonary capillary wedge pressure (r=0.82,P=0.007).Conclusions—We have shown that CNP is produced by the heart in patients with CHF. Although further evaluation is required to define its full pathophysiological role in this condition, CNP may represent an important new local mediator in the heart.
ISSN:0009-7322
出版商:OVID
年代:2003
数据来源: OVID
|
15. |
Differential Regulation of Natriuresis by 20-Hydroxyeicosatetraenoic Acid in Human Salt-Sensitive Versus Salt-Resistant Hypertension |
|
Circulation: Journal of the American Heart Association,
Volume 107,
Issue 4,
2003,
Page 574-578
Cheryl Laffer,
Michal Laniado-Schwartzman,
Mong-Heng Wang,
Alberto Nasjletti,
Fernando Elijovich,
Preview
|
PDF (85KB)
|
|
摘要:
Background—Twenty-hydroxyeicosatetraenoic acid (20-HETE) is a cytochrome P450 metabolite of arachidonic acid that produces vasoconstriction and inhibition of renal tubular sodium transport. In Dahl rats, a 20-HETE deficiency plays a role in salt-sensitive (SS) hypertension. In humans, there are no data on regulation of 20-HETE by salt intake or on a role for this compound in SS hypertension.Methods and Results—Thirteen salt-resistant (SR) and 13 SS hypertensive subjects had urine 20-HETE excretion measured during salt-loading and depletion. In all patients, 20-HETE was 66.6% higher in the salt-replete (1.75±0.25 &mgr;g/h) than in the salt-depleted state (1.05±0.16,P<0.003). There was no difference in 20-HETE excretion between SR and SS patients in either state of salt balance. In SR patients, sodium excretion during salt-loading correlated with 20-HETE (r=0.61,P<0.03) but not with blood pressure. In contrast, in SS patients, sodium excretion did not correlate with 20-HETE but did correlate with blood pressure (r=0.66,P<0.02). Finally, in the SS group only, there was a negative correlation between body mass index and 20-HETE excretion (r=−0.79,P<0.002) that was present during both salt-loading and depletion.Conclusions—We demonstrate for the first time that 20-HETE excretion is regulated by salt intake in hypertension. We find a disrupted relationship between sodium excretion and 20-HETE in SS patients, which results in dependence of their salt excretion on blood pressure and may be related to the magnitude of their obesity. We conclude that salt-sensitivity of blood pressure in essential hypertension may result from impairment of a natriuretic mechanism dependent on 20-HETE.
ISSN:0009-7322
出版商:OVID
年代:2003
数据来源: OVID
|
16. |
Angiotensin-Converting Enzyme Inhibition Increases Human Vascular Tissue-Type Plasminogen Activator Release Through Endogenous Bradykinin |
|
Circulation: Journal of the American Heart Association,
Volume 107,
Issue 4,
2003,
Page 579-585
Mias Pretorius,
David Rosenbaum,
Douglas Vaughan,
Nancy Brown,
Preview
|
PDF (177KB)
|
|
摘要:
Background—Angiotensin-converting enzyme (ACE) inhibition potentiates the tissue-type plasminogen activator (t-PA) response to exogenous bradykinin. This study tested the hypothesis that ACE inhibition increases endothelial t-PA release through endogenous bradykinin.Methods and Results—We measured the effect of intra-arterial enalaprilat (5 &mgr;g/min) on forearm blood flow (FBF) and net t-PA release before and during intra-arterial infusion of bradykinin (25 to 400 ng/min) and methacholine (3.2 to 12.8 &mgr;g/min) in 24 smokers pretreated with bradykinin receptor antagonist HOE 140 (100 &mgr;g/kg intravenously) or vehicle. There was no specific effect of HOE 140 on FBF or forearm vascular resistance (FVR, 29.9±3.6 versus 29.7±3.6 mm Hg · mL−1· min−1· 100 mL−1after vehicle and HOE 140, respectively,P=0.956 between groups). Resting FVR decreased during enalaprilat compared with vehicle or HOE 140, but not compared with baseline, and the effect was similar in the 2 groups (22.0±2.7 and 24.1±2.9 mm Hg · mL−1· min−1· 100 mL−1, respectively,P=0.610). In contrast, enalaprilat significantly increased resting net t-PA release (from 0.6±0.4 to 1.7±0.6 ng · min−1· 100 mL−1,P=0.002); this effect was abolished by HOE 140 (0.1±0.3 ng · min−1· 100 mL−1,P=0.036 versus enalaprilat alone). Enalaprilat increased the effect of exogenous bradykinin on FBF 60% (from 17.5±2.5 to 28.1±4.0 mL · min−1· 100 mL−1during 100 ng/min bradykinin,P=0.001) and on t-PA release 14-fold (from 21.2±7.9 to 317.4±118.9 ng · min−1· 100 mL−1,P=0.024). Enalaprilat increased the t-PA response to bradykinin to a greater extent than the FBF response, shifting the relationship between net t-PA release and FBF (P=0.005). HOE 140 blocked these effects. There was no effect of enalaprilat or HOE 140 on the FBF or t-PA response to methacholine.Conclusion—ACE inhibition increases constitutive endothelial t-PA release through endogenous bradykinin.
ISSN:0009-7322
出版商:OVID
年代:2003
数据来源: OVID
|
17. |
Diverse Effects of Increasing Lisinopril Doses on Lipid Abnormalities in Chronic Nephropathies |
|
Circulation: Journal of the American Heart Association,
Volume 107,
Issue 4,
2003,
Page 586-592
Piero Ruggenenti,
Naobumi Mise,
Roberto Pisoni,
Federica Arnoldi,
Anna Pezzotta,
Annalisa Perna,
Dario Cattaneo,
Giuseppe Remuzzi,
Preview
|
PDF (135KB)
|
|
摘要:
Background—Dyslipidemia frequently complicates chronic nephropathies and increases the risk of renal and cardiovascular events. This might be ameliorated by drugs, such as angiotensin-converting enzyme inhibitors, which effectively reduce proteinuria.Methods and Results—In this longitudinal study, we evaluated the extent to which uptitration of the ACE inhibitor lisinopril to maximum tolerated doses (median [range]: 30 [10 to 40] mg/d) ameliorated proteinuria and dyslipidemia in 28 patients with nondiabetic chronic nephropathies. Maximum lisinopril doses significantly and safely reduced proteinuria, serum total, LDL cholesterol, and triglycerides without substantially affecting serum HDL and renal hemodynamics. Proteinuria already decreased at 10 mg/d. Serum lipids progressively and dose-dependently decreased during uptitration to maximum doses. Reduction in total and LDL cholesterol correlated with increases in serum albumin/total protein concentration and oncotic pressure, peaked at lisinopril maximum doses, and persisted after treatment withdrawal. Despite less proteinuria reduction, hypercholesterolemia decreased more (and reflected the increase in serum albumin) in hypoalbuminemic than in normoalbuminemic patients who, despite more proteinuria reduction, had less decrease in cholesterol and no changes in serum albumin. Changes in serum triglycerides were independent of changes in serum proteins, were strongly correlated with lisinopril doses (r=−0.89,P=0.003) and recovered promptly after treatment withdrawal. Lisinopril was well tolerated, did not affect renal hemodynamics, and caused symptomatic, reversible hypotension in only two patients.Conclusions—In chronic nephropathies, angiotensin converting enzyme inhibitor uptitration to maximum tolerated doses safely ameliorated hypertriglyceridemia by a direct, dose-dependent effect, and hypercholesterolemia through amelioration of the nephrotic syndrome, particularly in patients with more severe hypoalbuminemia.
ISSN:0009-7322
出版商:OVID
年代:2003
数据来源: OVID
|
18. |
Combination of a Normal D-Dimer Concentration and a Non-High Pretest Clinical Probability Score Is a Safe Strategy to Exclude Deep Venous Thrombosis |
|
Circulation: Journal of the American Heart Association,
Volume 107,
Issue 4,
2003,
Page 593-597
R. Schutgens,
P. Ackermark,
F. Haas,
H. Nieuwenhuis,
H. Peltenburg,
A. Pijlman,
M. Pruijm,
R. Oltmans,
J. Kelder,
D. Biesma,
Preview
|
PDF (50KB)
|
|
摘要:
Background—Serial ultrasonography is reliable for the diagnosis of deep venous thrombosis in symptomatic patients, but the low prevalence of thrombosis in this group renders the approach costly and inconvenient to patients. We studied the clinical validity of the combination of a pretest clinical probability score and a D-dimer test in the initial evaluation of patients suspected of deep venous thrombosis.Methods and Results—Patients with a normal D-dimer concentration (<500 fibrin equivalent units [FEU] &mgr;g/L) and a non-high probability score (<3) had no further testing. Patients with a normal D-dimer concentration and a high probability score (≥3) underwent one ultrasonogram. Serial ultrasonography was performed in patients with an abnormal D-dimer concentration. Patients were followed for 3 months. A total of 812 patients were evaluable for efficacy. Only 1 of 176 patients (0.6%; 95% CI, 0.02% to 3.1%) with a normal D-dimer concentration and a non-high probability score developed thrombosis during follow-up. A normal D-dimer concentration and a high probability score were found in 39 patients; 3 of them (7.7%; 95% CI, 1.6% to 20.9%) had thrombosis at presentation, and one (2.8%; 95% CI, 0.07% to 14. 5%) developed pulmonary embolism during follow-up. In 306 of 597 patients (51.3%) with an abnormal D-dimer concentration, thrombosis was detected by serial ultrasonography. Six patients (2.1%; 95% CI, 0.8% to 4. 4%) developed thrombosis during follow-up. No deaths due to thromboembolism occurred during follow-up. The total need for ultrasonography was reduced by 29%.Conclusion—The combination of a non-high pretest clinical probability score and a normal D-dimer concentration is a safe strategy to rule out deep venous thrombosis and to withhold anticoagulation.
ISSN:0009-7322
出版商:OVID
年代:2003
数据来源: OVID
|
19. |
Matrix Metalloproteinase-9 Pretreatment Level Predicts Intracranial Hemorrhagic Complications After Thrombolysis in Human Stroke |
|
Circulation: Journal of the American Heart Association,
Volume 107,
Issue 4,
2003,
Page 598-603
Joan Montaner,
Carlos Molina,
Jasone Monasterio,
Sonia Abilleira,
Juan Arenillas,
Marc Ribó,
Manolo Quintana,
José Alvarez-Sabín,
Preview
|
PDF (139KB)
|
|
摘要:
Background—Matrix metalloproteinase (MMP) expression is related to blood brain barrier disruption after cerebral ischemia. Moreover, MMP inhibitors reduce hemorrhagic transformation (HT) after embolic ischemia in tissue plasminogen activator (t-PA)–treated animals. We aimed to correlate plasmatic MMP levels with the appearance of intracranial bleeding complications in stroke patients treated with t-PA.Methods and Results—Serial MMP-2 and MMP-9 determinations were performed (ELISA, ng/mL) in 41 strokes involving the middle cerebral artery territory in patients who received t-PA within 3 hours of stroke onset. Blood samples were obtained at baseline (pretreatment) and at 12 and 24 hours after symptom onset. Hemorrhagic events were classified according to CT criteria (petechial hemorrhagic infarctions [HI, 1 to 2] and large parenchymal hemorrhages [PH, 1 to 2]). Brain CT scan was obtained at 48 hours or when a neurological worsening occurred. HT was present in 36.5% of the patients (24.4% HI and 12.1% PH). MMP-2 values were unrelated to any subtype of HT. The highest baseline MMP-9 level (normal range <97 ng/mL) corresponded to patients who later developed a PH (PH: 270.2±87.8, non-HT: 126.3±127.5, HI: 94.6±88.7;P=0.047). A graded response was found between mean baseline MMP-9 levels and the degree of bleeding (HI-1=37.4; HI-2=111.0; PH-1=202.5; PH-2=337.8). Baseline MMP-9 was the most powerful predictor of PH appearance in the multiple logistic regression model (OR= 9.62; CI 1.31 to 70.26;P=0.025).Conclusions—Baseline MMP-9 level predicts PH appearance after t-PA treatment. Therefore, we suggest that MMP determination may increase the safety profile for thrombolysis and, in the future, anti-MMP drugs might be combined with t-PA to prevent hemorrhagic complications.
ISSN:0009-7322
出版商:OVID
年代:2003
数据来源: OVID
|
20. |
Nicotine Strongly Activates Dendritic Cell–Mediated Adaptive ImmunityPotential Role for Progression of Atherosclerotic Lesions |
|
Circulation: Journal of the American Heart Association,
Volume 107,
Issue 4,
2003,
Page 604-611
Alexandra Aicher,
Christopher Heeschen,
Mariette Mohaupt,
John Cooke,
Andreas Zeiher,
Stefanie Dimmeler,
Preview
|
PDF (340KB)
|
|
摘要:
Background—Antigen-presenting cells (APCs) such as monocytes and dendritic cells (DCs) stimulate T-cell proliferation and activation in the course of adaptive immunity. This cellular interaction plays a role in the growth of atherosclerotic plaques. Nicotine has been shown to increase the growth of atherosclerotic lesions. Therefore, we investigated whether nicotine can stimulate APCs and their T cell–stimulatory capacity using human monocyte–derived DCs and murine bone marrow–derived DCs as APCs.Methods and Results—Nicotine dose-dependently (10−8to 10−4mol/L) induced DC expression of costimulatory molecules (ie, CD86, CD40), MHC class II, and adhesion molecules (ie, LFA-1, CD54). Moreover, nicotine induced a 7.0-fold increase in secretion of the proinflammatory TH1 cytokine interleukin-12 by human DCs. These effects were abrogated by the nicotinic receptor antagonist &agr;-bungarotoxin and mecamylamine, respectively. The effects of nicotine were mediated in part by the phosphorylation of the PI3 kinase downstream target Akt and the mitogen-activated kinases ERK and p38 MAPK. Nicotine-stimulated APCs had a greater capacity to stimulate T-cell proliferation and cytokine secretion, as documented by mixed lymphocyte reactions and ovalbumin-specific assays with ovalbumin-transgenic DO10.11 mice. In a murine model of atherosclerosis, nicotine significantly enhanced the recruitment of DCs to atherosclerotic lesions in vivo.Conclusions—Nicotine activates DCs and augments their capacity to stimulate T-cell proliferation and cytokine secretion. These effects of nicotine may contribute to its influence on the progression of atherosclerotic lesions.
ISSN:0009-7322
出版商:OVID
年代:2003
数据来源: OVID
|
|